MEDICAL COMMUNITY

Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of …

Positive Phase III data for migraine drug Fremanezumab Read More »

OBJECTIVES: The aim of this study was to evaluate the efficacy of greater occipital nerve (GON) block in the treatment of migraine patients. METHODS: This study included 28 patients diagnosed with migraine between 2014 and 2015. The GON block procedure was applied by administering 1.5 ml of 2% lidocaine 2 cm lateral and 2 cm …

The results of greater occipital nerve block applied for migraine headache Read More »